158 results about "Synovial membrane" patented technology

The invention provides an organ chip unit for simulating the pathogenesis of rheumatoid arthritis, and belongs to the technical field of cell culture. The chip comprises a top-layer chip, a bottom-layer chip and a middle microporous membrane, the top-layer chip and the bottom-layer chip are separated by the middle microporous membrane, and the middle microporous membrane is used for enabling cells in a cell culture space of the top-layer chip and cells in a cell culture space of the bottom-layer chip not to be in direct contact, but interaction of signal molecules and substance exchange can be carried out; synovial cells and cartilage cells are injected into the bottom-layer chip or the top-layer chip to be cultured. According to the invention, multi-cell three-dimensional co-culture can be realized. Through the additional stress stimulation co-culture part, the influence of pressure or tension on the cell environment can be judged, and the actual condition that rheumatoid arthritis joints receive pressure or tension for a long time can be simulated. The synovial cells and the cartilage cells are used, so that the structure of the inflammation joint in a living body can be truly reflected, and the interaction among various cell tissues can be reflected.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

A weft yarn for an artificial ligament (1), a weft yarn preparation method, and an artificial ligament (1). The artificial ligament (1) is of a round rod structure; a first woven part (102), an in-joint free filament part (103), and a second woven part (104) which are sequentially connected are formed in the round rod structure in the axial direction thereof; the in-joint free filament part (103) comprises a plurality of weft yarns (201), and the weft yarns (201) extend in the axial direction of the round rod structure; and each weft yarn (201) has a fineness of 1000 D-3000 D / 1-100 F, and a mechanical strength of 75-300 N. By increasing the mechanical strength of a single yarn formed in the in-joint free filament part (103) of the artificial ligament (1), the number of yarns in the in-joint free filament part (103) is decreased. The present invention can eliminate a knee joint synovial membrane inflammatory response caused by chippings of the artificial ligament (1) in the reconstruction process of the artificial ligament (1), reduce the degree of contact adhesion between the in-joint free filament part (103) and the tissue, reduce the probability of adhesion, and solve the clinical problems of the inflammatory response and the prolonged surgery time which are caused by difficult removal due to adhesion of the free filaments and the tissue in the revision surgery.

The invention discloses a low-temperature plasma-based portable joint inflammation accurate therapeutic apparatus, and relates to the technical field of arthritis treatment, the low-temperature plasma-based portable joint inflammation accurate therapeutic apparatus comprises a shell, the lower end of the shell is fixedly connected with a first magnetic type interface, the interior of the shell is fixedly connected with a graphene heat-conducting fin, the front end of the graphene heat-conducting fin is fixedly connected with a circuit board, and the circuit board is fixedly connected with a power supply. A plasma generator, a battery, an ozone neutralization module, a communication module and a control chip are fixedly installed at the front end of the circuit board, through a magnetic attraction structure of the first magnetic attraction type interface and the second magnetic attraction type interface, in cooperation with mechanical positioning of the positioning block and the butt joint groove, rapid replacement of the treatment probe is achieved, and by replacing probes of different forms, the treatment efficiency is improved. The probe can adapt to complex joint contours, a miniature ultrasonic transducer is integrated in the probe, tissue gaps can be temporarily expanded by means of the cavitation effect of ultrasonic waves, the penetration depth of plasma active particles is increased, and the probe effectively acts on deep synovial tissues.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The invention provides a universal drug targeting delivery system for constructing pathological fibroblast-like synovial cells in osteoarthritis and application of the universal drug targeting delivery system. According to the drug targeting delivery system, vasoactive intestinal peptide is modified to the surface of polydopamine-coated large-aperture calcium ion-doped silicon dioxide; the vasoactive intestinal peptide specifically targets a VPAC1 receptor, and targeted delivery of the nano-drug to pathological fibroblast-like synovial cells in osteoarthritis is successfully realized. The vasoactive intestinal peptide provided by the invention is a polypeptide, has abundant amino groups and carboxyl groups, and can be connected to a drug delivery carrier through a simple chemical reaction, so that efficient targeted delivery of drugs and accumulation of pathological cells are realized.

The invention relates to application of a miR-155-5p inhibitor delivered by an exosome of a targeted synovitis macrophage to treatment of osteoarthritis, and belongs to the technical field of biological medicines. According to the scheme, the exosome drug delivery system for targeting the synovial inflammatory macrophages in the osteoarthritis, which contains the miR-155-5p inhibitor, is prepared through a genetic engineering technology, so that the exosome derived from stem cells is targeted to inflammatory synovial tissues, and damaged cartilage tissues are repaired and inflammation is resisted based on the stem cell exosome; compared with the prior art, the application has the advantages that the combined action of inhibiting the osteoarthritis injury and inhibiting the miR-155-5p so as to resist synovitis is realized, the osteoarthritis injury repair can be better applicable, a new scheme for treating the osteoarthritis is provided, a support is provided for clinical transformation, and the application value is extremely high.

The invention belongs to the field of biomedicine, and provides application of LDHA as a treatment target of aging-related osteoarthritis. In-vitro cell experiments and animal in-vivo experiments prove that the LDHA inhibitor can inhibit OA progress caused by aging, and targeted inhibition of LDHA in synovial fibroblasts can provide a brand-new treatment strategy for treatment of aging-related osteoarthritis.

The application provides a kind of load exosome composite hydrogel and preparation method thereof, belong to biomaterial and drug delivery technical field;Its preparation method includes: modified chitosan;Modified hyaluronic acid;Preparation of biphasic calcium phosphate nanoparticles;Preparation of composite hydrogel.The application is through nucleophilic ring-opening reaction of 1,2-epoxy butane and the hydroxyl group of chitosan, form hydroxybutyl ether bond, give hydroxybutyl chitosan temperature sensitive characteristics, then, again, after activation 3,4-dihydroxyphenylalanine is condensed with hydroxybutyl chitosan, form amide bond, to graft 3,4-dihydroxyphenylalanine on hydroxybutyl chitosan, after modification of chitosan, 3,4-dihydroxyphenylalanine can form strong adhesion interface with cartilage, synovial membrane and other tissues through hydrogen bond, pi-pi stacking and metal coordination, thereby effectively prolonging the residence time of hydrogel in joint.

The invention belongs to the field of biological medicine, and discloses a chicoric acid (CA)-loaded tetrahedral framework nucleic acid (tFNA) nano preparation for treating acute gouty arthritis. According to the preparation, tFNA formed by self-assembly is taken as a carrier, and a natural active ingredient CA is loaded to form a CA-tFNA compound. The compound overcomes the defects that CA is poor in water solubility and low in bioavailability, and existing drugs are weak in targeting and large in side effect. Through the targeted delivery and synergistic effect of tFNA, the preparation can be effectively enriched in inflammatory joints, significantly inhibit NF-kappa B signal pathways, and down-regulate the expression of key proinflammatory factors such as TNF-alpha and IL-1beta, so that joint swelling and synovial tissue damage are relieved, and repair is promoted. Experiments show that the traditional Chinese medicine composition is remarkable in curative effect and good in safety, and a novel efficient treatment strategy is provided for acute gouty arthritis.

The present invention relates to a composition and method for treating rheumatoid arthritis, comprising interleukins (ILs), including IL-1β, stimulated human umbilical cord mesenchymal stem cells (hUCMSCs). The IL stimulated hUCMSCs of the present invention may induce the apoptosis of fibroblast-like synoviocytes rheumatoid arthritis (HFLS-RA) cells. IL stimulated hUCMSCs are useful to alleviate RA symptoms, such as inflammation, swelling and cartilage erosion, and exhibit therapeutic effects on rheumatoid arthritis.

The microneedle diagnosis and treatment device comprises a sensing microneedle, a photo-thermal microneedle, a light source module, an electrochemical sensing module, a main control module and an upper computer, the sensing microneedle and the photo-thermal microneedle are respectively and electrically connected with the electrochemical sensing module, the light source module and the electrochemical sensing module are respectively and electrically connected with the main control module, and the main control module is in communication connection with the upper computer. The sensing microneedle disclosed by the invention is matched with the electrochemical sensing module and the main control module, so that the change of the glucose level in joint tissue fluid can be monitored in real time, and monitored data is transmitted to an upper computer through the main control module; a user can utilize the host computer to cooperate with the master control module to control the operation of the light source module, so that the photo-thermal microneedle absorbs light energy and generates high temperature, thereby inhibiting synovial hyperplasia of tissue fluid and achieving the purpose of integration of monitoring and treatment, the structure is simple, and closed-loop management of monitoring-evaluation-treatment can be realized.

The invention discloses an application of TRBC2 in diagnosis of gout. According to the application, a recognized moving meniscus tearing patient (equivalent to a completely healthy synovial tissue) without gout medical history is taken as a contrast, single cell transcriptome analysis is carried out on the basis of a clinical biological sample, and a marker TRBC2 of a T cell subset is found to have significant difference in gout patients; a Raman spectrum technology is further adopted to find that the TRBC2 protein is specifically and highly expressed in synovial tissues of gouty arthritis patients and has relatively high diagnosis efficiency, and the TRBC2 is relatively high in clinical value and wide in application prospect when being used as a marker for diagnosing gout.

The invention belongs to the technical field of medicine technology, particularly relates to application of isochlorogenic acid C in medicine for treating inflammation, and provides novel application of isochlorogenic acid C in preparation of anti-inflammation medicine, and particularly has a good inhibition effect on abnormal behaviors such as invasion of synovial fibroblasts and secretion of inflammatory factors. Isochlorogenic acid C is provided as an effective medicine component for treating arthritis, and the main action mechanism is to inhibit invasion of RA-FLS and secretion of IL-6 so as to relieve clinical symptoms; the innovation of the invention lies in that: the invention provides treatment of inflammation based on isochlorogenic acid C, and through application of a specific dosage, joint inflammation of patients can be effectively relieved and joint functions can be improved.

The invention provides a traditional Chinese medicine preparation for dispelling wind and eliminating dampness and application, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of honeysuckle stem, spatholobus stem, silkworm excrement, gentian, safflower, peach kernel, ash bark, arisaema cum bile, medicated leaven and honeycomb; the traditional Chinese medicine preparation can remarkably reduce the ankle joint swelling degree of an acute gouty arthritis model rat, reduce the expression level of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in serum and reduce the content of uric acid, creatinine and XOD in the serum, so that the effects of resisting inflammation, easing pain and reducing blood uric acid are achieved; clinical test results show that the traditional Chinese medicine preparation can relieve the pain degree of a patient, reduce the levels of inflammation-related factors TNF-alpha and IL-1beta in knee joint synovial fluid of the patient, reduce inflammation indexes WBC, ESR and CRP in serum, relieve the inflammatory reaction of the body of the patient, reduce the occurrence rate of adverse reactions, and improve the curative effect of the patient. A novel traditional Chinese medicine preparation with high safety and good curative effect is provided for treatment of acute gout.

The drainage pipeline structure comprises a drainage blind ditch, a communication part and a drainage part, the drainage blind ditch is arranged between a rock mass surface and a vertical shaft lining, and the drainage blind ditch is used for collecting leakage water of a rock mass; the communicating part comprises a three-way connecting piece, a pre-buried drainage pipe and a filling material, the pre-buried drainage pipe extends in the thickness direction of the vertical shaft lining and penetrates through the vertical shaft lining, the three-way connecting piece communicates with the drainage blind ditch and the pre-buried drainage pipe, and the filling material is arranged on the side, away from the three-way connecting piece, of the pre-buried drainage pipe and detachably connected with the pre-buried drainage pipe; the end parts of the embedded drainage pipe and the filling material do not exceed the inner wall surface of the vertical shaft lining; and the drainage part is configured to be connected with the pre-embedded drainage pipe after the filling material is detached, and the drainage part is used for draining leakage water. The drainage pipeline structure for the slip form construction does not affect normal construction of the slip form, and can ensure safe drainage of mountain leakage water after the slip form construction is completed.

The invention relates to the technical field of new application of sinomenine, and discloses application of sinomenine in preparation of drugs. The invention relates to application of sinomenine in preparation of drugs for inhibiting RA synovial fibroblast proliferation and the like. The sinomenine can significantly inhibit the proliferation of RA-FLS, and plays a role in inducing cell apoptosis at the G0 / G1 phase by retarding the cell cycle. The sinomenine can also be used for remarkably inhibiting the phosphorylation level of downstream effector molecules p70S6K and 4E-BP1 of the mTOR. The sinomenine can also be combined with RNF7 in a targeted manner to inhibit an mTOR signal channel.

The invention relates to the technical field of biological medicine, in particular to a biomarker for diagnosing and distinguishing rheumatoid arthritis and knee osteoarthritis and application of the biomarker. In order to solve the problems of insufficient sensitivity and specificity of rheumatoid arthritis (RA) and knee osteoarthritis (KOA) in clinical detection, the invention discloses a novel biomarker, namely a soluble interleukin 17 receptor D, namely sIL-17RD. The inventor finds that the sIL-17RD level is remarkably increased in serum of a patient with rheumatoid arthritis, the sIL-17RD level is not remarkably changed in serum of a patient with knee osteoarthritis, and the sIL-17RD level is remarkably increased in synovial fluid of the patient with knee osteoarthritis. Therefore, by measuring the sIL-17RD level in the serum sample of the rheumatoid arthritis patient and the sIL-17RD level in the synovial fluid and serum of the knee osteoarthritis patient, the rheumatoid arthritis and the knee osteoarthritis are diagnosed and distinguished, and a new strategy is provided for clinical diagnosis and distinguishing of the rheumatoid arthritis and the knee osteoarthritis.

The invention discloses a rheumatoid arthritis targeted therapeutic drug and a preparation method thereof, and relates to the field of medicines. The invention relates to an acid response nano-particle CEC NPs, which is specifically composed of the following components: a carrier, which is an M2 type macrophage derived exosome; and loading the medicine. According to the acid response nano-particles based on the CXB and the CC-90011 loaded on the exosome derived from the M2 type macrophage, the M2Exo can specifically target an inflammatory environment, and the specific anti-inflammatory biological function of the M2Exo can be exerted; under the acidic condition, CEC NPs responds to release CE NPs and CC-90011, the CE NPs can repolarize M1 type macrophages and inhibit FLS activation to effectively relieve arthritis inflammatory response and synovial hyperplasia, and the CC-90011 can inhibit LSD1 to interfere the energy metabolism pathway of osteoclasts and inhibit osteoclast formation, so that the pathological bone resorption process is blocked, and bone erosion is relieved.

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.

The invention discloses a construction method of a synovial sarcoma tumor ball vascular induction model, the model and application of the synovial sarcoma tumor ball vascular induction model. The construction method of the synovial sarcoma tumor sphere vascular induction model comprises the following steps: S1, suspension culture of synovial sarcoma organs; and S2, constructing a synovial sarcoma tumor ball vascular induction model based on the culture chip. When the synovial sarcoma organ is cultured, the synovial sarcoma primary tissue is cultured in a suspension culture mode, and the method not only can improve the proliferation speed of the synovial sarcoma organ, the cell growth state is better, the activity is higher, but also has the advantage of simplicity in operation. Besides, the synovial sarcoma tumor sphere vascular induction model is constructed based on the culture chip, and the model can simulate tumor microenvironment more truly, has tumor-related fibroblast and vascular components, and provides more clinical drug sensitivity test results.

The invention provides a muscle-bone injury area identification method and system, and relates to the technical field of muscle-bone image injury identification. The method comprises the following steps: acquiring a two-dimensional gray-scale ultrasonic image of a target muscle-bone injury area, and positioning a synovial tissue area from the two-dimensional gray-scale ultrasonic image; extracting target feature information from the synovial tissue region; and determining the inflammation activity degree of the synovial tissue according to the target feature information. According to the method, Doppler blood flow signals are completely bypassed, the rheumatism inflammation activity degree is evaluated only through rich information contained in the two-dimensional gray-scale ultrasonic image, and therefore interference of probe pressure artifacts is thoroughly avoided.

The invention discloses a pathological microenvironment self-driven precise targeting nano-robot as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing an MOF carrier; (2) preparing MOF-coated ISLamp; a CORM-401 compound, and an organic solvent; (3) preparing apoptotic cell membranes; (4) preparing an FH peptide modified apoptosis cell membrane: coupling the FH peptide with a synthetic sequence of FHKHKSPALSPV with DSPE-PEG-NHS, then mixing with apM, carrying out ultrasonic treatment, and carrying out centrifugal purification to obtain FM; (5) preparing a nano robot: MOF (at) ISLamp; the CORM-401 and the FM membrane protein are mixed, asymmetrically wrapped, extruded to pass through a membrane, and centrifuged to obtain the nano-robot. According to the designed self-driven nano-robot integrating the triple functions of self-driving, precise targeting and collaborative treatment, CORM-401-ROS reaction is used for providing active power to break through a synovial membrane barrier, targeted enrichment of core pathological cells is achieved through an engineered cell membrane, the mitochondrial function is synergistically repaired by means of ISL and CO, OA pathological circulation is blocked, and the targeted enrichment of the core pathological cells is achieved. A brand new technical scheme is provided for treatment of osteoarthritis from symptomatic remission to pathological reversion.

The application discloses a kind of nanoclusters with golgi targeting and its preparation method and application, the nanocluster is zinc sulfide nanocluster, the surface of the zinc sulfide nanocluster is coupled with targeting ligand, the targeting ligand can actively target RA synovial activated macrophage, and can target golgi subcellular organelle, the nanocluster can release H2S gas in inflammatory weak acid microenvironment.The application can realize "inflammatory joint enrichment-> macrophage active uptake-> lysosome escape-> golgi deep anchoring" multi-level precise delivery, release H2S gas in inflammatory weak acid microenvironment, fundamentally reshape intracellular Ca 2+ Steady state, relieve endoplasmic reticulum, golgi and mitochondria triple stress, block inflammatory signal pathway, realize the efficient, safe treatment of RA.

Provided herein are methods and compositions for treating cancer. In some cases, the cancer comprises soft tissue sarcoma, such as synovial sarcoma. In some cases, the treatment comprises administering a therapeutically effective amount of an SS18-SSX fusion protein inhibitor to the subject. In some cases, the treatment comprises administering a therapeutically effective amount of SUMO2 inhibitor to the subject. The subject can be a pediatric subject or an adult subject.

A wearable patch configured to support synovial joints of the human body is disclosed. The patch has a base layer that is flexible to conform to the contours of the area of the human body to which the wearable patch is applied. The base layer has a first side and a second side. The second side is configured to adhere the wearable patch to the human body. The patch also has a plurality of tiles provided on the first side of the base layer. The plurality of tiles has an array of repeated shapes. The plurality of tiles are connected to the base layer such that each tile can pivot relative to an adjacent tile.

The application provides a pharmaceutical composition for treating rheumatoid arthritis, which is composed of paeoniflorin, glycyrrhizin, glycyrrhizic acid and glycyrrhetic acid in a weight ratio of (4.5-7.5):(0.4-1.8):(1.8-4.3):(22-40). The pharmaceutical composition can significantly inhibit the proliferation of fibroblast-like synoviocytes, reduce the secretion of inflammation-related factors (TNF-alpha, IL-1beta, IL-6 and COX-2), regulate the expression of TNF-alpha / NF-kappaB signal pathway-related proteins, and has a significant curative effect on rheumatoid arthritis.

The application discloses a pathological microenvironment self-driven precise targeted nanorobot and a preparation method and application thereof, and is prepared according to the following steps: (1) preparing a MOF carrier; (2) preparing a MOF@ISL&CORM-401 compound; (3) preparing an apoptotic cell membrane; (4) preparing an FH peptide modified apoptotic cell membrane: coupling FH peptide with a sequence of FHKHKSPALSPV and DSPE-PEG-NHS, mixing with apM under ultrasonic, centrifugal purification, and obtaining FM; (5) preparing a nanorobot: mixing the MOF@ISL&CORM-401 and the membrane protein of FM, asymmetrically wrapping, extruding through the membrane, and centrifugal to obtain the nanorobot. The self-driven nanorobot with the triple functions of self-driving, precise targeting and synergistic treatment is designed, the CORM-401-ROS reaction is utilized to provide active power to break through the synovial membrane barrier, the engineered cell membrane is utilized to realize the targeted enrichment of core pathological cells, the ISL and CO are utilized to repair the mitochondrial function, and the OA pathological cycle is blocked, so that a novel technical scheme is provided for the treatment of osteoarthritis from the symptomatic relief to the pathological reversal.

The invention provides a synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability and a separation method, an identification method and application thereof, the cell surface of the synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability simultaneously expresses CDH13 and CD90, and the expression of NOTCH3 is deleted or the expression level of NOTCH3 is lower than a preset threshold value. The synovial stem cell subgroup with the spontaneous chondrogenic differentiation capacity is obtained and can be spontaneously differentiated into chondrocytes under the basic culture condition without adding growth factors, and better seed cells are provided for articular cartilage injury repair; the problems of inaccurate cartilage regeneration seed cell source, tedious induction steps and the like in the prior art are solved.

This invention discloses a novel application of the RNA-binding protein HNRNPA1 in regulating copper death in synovial fibroblasts of rheumatoid arthritis (RA-FLS). Overexpression of HNRNPA1 recognizes and binds to the m6A modification site of SLC3A2 mRNA, enhancing its transcript stability, restoring the expression of SLC3A2 and copper death-related proteins, reducing MDA levels, increasing copper ion concentration and the activity of antioxidant enzymes SOD and POD, thereby repairing mitochondrial ultrastructural damage, inhibiting abnormal cell proliferation, and inducing apoptosis. Reversal experiments confirmed that knocking down SLC3A2 reverses the above effects, indicating that SLC3A2 is a core downstream target of HNRNPA1-mediated copper death. This invention reveals for the first time the decisive role of the HNRNPA1-SLC3A2-copper death axis in the pathological phenotype of RA-FLS, providing a new target for molecular intervention in rheumatoid arthritis.